What is Vertex Pharmaceuticals's tax reconciliation: research and other credits?

Vertex Pharmaceuticals (VRTX) reported tax reconciliation: research and other credits of $0.01 in Q4 2025.

What does tax reconciliation: research and other credits mean?

The effect of R&D tax incentives on the effective tax rate.

Discontinued — last reported Q4 '19

Tax Reconciliation: Research and Other Credits

Vertex Pharmaceuticals Tax Reconciliation: Research and Other Credits remained flat by 0.0% to $0.01 in Q4 2025 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementIncome Statement

SectionTax

CategoryProfitability

SignalHigher is better

VolatilityModerate

First reportedQ1 2013

Last reportedQ4 2019

How to read this metric

An increase indicates a greater reliance on or success in capturing R&D tax benefits to improve bottom-line profitability.

Detailed definition

The impact of research and development tax credits on the effective tax rate reconciliation. It highlights the extent to...

Peer comparison

Standard metric for R&D-heavy companies to demonstrate tax efficiency.

Metric ID: is_cat_tax_reconciliation_research_credits

Historical Data

1 years

	FY'25
Value	$0.03

Frequently Asked Questions

What is Vertex Pharmaceuticals's tax reconciliation: research and other credits?: Vertex Pharmaceuticals (VRTX) reported tax reconciliation: research and other credits of $0.01 in Q4 2025.
What does tax reconciliation: research and other credits mean?: The effect of R&D tax incentives on the effective tax rate.